ArticleScientific reports2026
Performance optimization of ultra-lightweight foamed concrete using dimethicone-infused organosilicon compound.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study investigated the solid-phase modification of ultralightweight foamed concrete (ULFC) cementitious composites using dimethicone compound at five different concentrations (0.5%, 1.0%, 1.5%, 2.0%, and 2.5% by weight). This research focused on studying the characteristics of dimethicone-based ULFC, including its fresh, mechanical, pore structure, and thermal properties. In this study, we examined the characteristics of fresh concrete, such as the time it takes to set initially and finally (Si, Sf), its workability, and its wet density. The transport characteristics, such as the sorptivity coefficient (S), water absorption (Wa), intrinsic permeability (IP), and rapid chloride permeability (RCP), underwent testing. The mechanical characteristics examined included compressive strength (fc), splitting tensile strength (ft), flexural strength (ff), modulus of elasticity (E), and dry shrinkage (Sh). The measurements of dry density and oven (D), porosity, dispersion, scanning electron microscopy (SEM), pore organization, thermal conductivity (K), and diffusivity (α) were conducted. The results indicated that by increasing the foam to a density of 49.4 kg/m³, it was possible to generate ULFC with a dry density of 450 kg/m³. Incorporating 0.5–2.5% dimethicone into ULFC mixes enhanced the properties of fresh, transport, mechanical, pore organization, and dry density, while raising the thermal conductivity and diffusion by 22% and 9.8%, respectively. The incorporation of 2% dimethicone into ULFC blends enhanced the workability and initial and final setting time by 8%, 61%, and 28% and reduced both the dry and oven-dried density by 1.3% and 1.25%, respectively. Its inclusion resulted in a 27% improvement in S, a 17.7% improvement in Wa%, a 22.5% improvement in IP, and a 30% improvement in RCP as transport characterizations at 28 days of age. The inclusion of this material significantly enhanced the mechanical properties of the control mix, which improved fc, ft, ff, E, and Sh by 182%, 237%, 200%, 207%, and 48%, respectively, at 28 days. The inclusion of a 2% additive resulted in a pore arrangement improvement that was almost comparable to that of a 2.5% additive. The 2% additive enhanced the porosity, small capillary pores, and average particle size by 8%, 18%, and 46%, respectively, after 28 days. These results were consistent with the SEM results. Dimethicone can be used successfully to improve the water resistance and mechanical properties of ULFC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.